AB0793 LONG-TERM USE OF AMTOLMETIN GUACIL IN PATIENTS WITH OSTEOARTHRITIS, RHEUMATOID ARTHRITISAND ANKYLOSING SPONDYLITIS

Abstract

Background: Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) is used to control of chronic pain in osteoarthritis (OA), rheumatoid arthritis (RA) and to prevent the progression of ankylosing spondyloarthritis (AS). Amtolmetin guacil (AMG), which has a low risk of gastrointestinal complications, may have advantages for long-term use. Objectives: To evaluate the effect and safety of long-term use of aMG. Methods: AMG 600-1800 mg/day was prescribed to 442 patients with OA (60.6 + 10.2 years, women 88.7%), 126 with RA (55.0 + 14.0 years, women 84.2%) and 73 with the aS (47.0 + 12.0 years, women 30.0%). The primary end point was the dynamics of pain on a numerical rating scale (NRS), additional for OA - WOMAC pain and HAQ, for RA - DAS28-CRP, for aS - BASDAI, BASFI and aSDAS-CRP. The result of treatment was evaluated on 3 consecutive visits after 3 months (9 months of treatment). Results: After 9 months 65.2% of OA patients, 75.3% of RA patients, and 82.2% of aS patients continued to take aMG. In end of study, the median of pain decreased with OA from 5.6 [4.1–6.9] to 3.4 [1.7–5.1], with RA from 5.8 [4.0–7.5] to 3.4 [2.0-4.8], with aS from 5.8 [4.2-7.5] to 3.1 [1.5-5.0] NRS (p <0.001). In OA WOMAC pain decreased from 127 [24-159] to 13.7 [14-40], p <0.001, HAQ from 0.54 ± 0.44 to 0.34 ± 0.26, p <0.001. With RA, the average value of DAS28 decreased from 4.81 + 1.18 to 4.30 + 1.24, p <0.05. In aS, the median BASDAI index decreased from 4.5 [1.0–8.0] to 3.0 [0–8.0], p <0.001. The number of aS patients with high activity on the aSDAS-CRP index (> 3.5) decreased from 76.9% to 25.8%, p <0.001. The BASFI index has not changed. 77.9% of patients with OA, 77.0% of patients with RA, and 74.5% of patients with aS were satisfied with the results of aMG treatment. AMG tolerability was good. 15-25% patients had mild dyspepsia. Discontinuation of therapy due to side effects was only in 6 patients (0.93%). The development or worsening of arterial hypertension, as well as other cardiovascular complications, was not observed. Conclusion: AMG is an effective, well-tolerated NSAID, which is appropriate for long-term treatment of OA, RA and aS. Disclosure of interests: None declared